Cargando…

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

Gain-of-function Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations occur in 25% of lung adenocarcinomas, and these tumors are challenging to treat. Some preclinical work, largely based on cell lines, suggested KRAS(mut) lung cancers are especially dependent on the nuclear export protein ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosen, Joshua C., Weiss, Jessica, Pham, Nhu-An, Li, Quan, Martins-Filho, Sebastiao N., Wang, Yuhui, Tsao, Ming-Sound, Moghal, Nadeem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313753/ https://www.ncbi.nlm.nih.gov/pubmed/34284202 http://dx.doi.org/10.1016/j.tranon.2021.101179

Ejemplares similares

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
por: Deng, Manman, et al.
Publicado: (2020)

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
por: Baek, Han Bit, et al.
Publicado: (2018)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
por: Binder, Adam F., et al.
Publicado: (2023)

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
por: Long, Huideng, et al.
Publicado: (2023)

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
por: Galinski, Basia, et al.
Publicado: (2021)

Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
por: Weiss, Jessica, et al.
Publicado: (2022)

Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes
por: Mirhadi, Shideh, et al.
Publicado: (2022)

The NRF2 antagonist ML385 inhibits PI3K‐mTOR signaling and growth of lung squamous cell carcinoma cells
por: Ji, Lili, et al.
Publicado: (2022)

Direct GDP-KRAS(G12C) inhibitors and mechanisms of resistance: the tip of the iceberg
por: Rosen, Joshua C., et al.
Publicado: (2023)

PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC
por: Ji, Lili, et al.
Publicado: (2019)

Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers
por: Pham, Nhu-An, et al.
Publicado: (2021)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
por: Brana, Irene, et al.
Publicado: (2017)

Selinexor for multiple myeloma
Publicado: (2022)

Proteomics identify nuclear export as a targetable pathway in neuroblastoma: Comment on “XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IκB”
por: Shah, Nilay
Publicado: (2021)

Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non–Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion()()
por: Hao, Jing, et al.
Publicado: (2019)

Patient-derived cell line, xenograft and organoid models in lung cancer therapy
por: Huo, Ku-Geng, et al.
Publicado: (2020)

Selinexor: Targeting a novel pathway in multiple myeloma
por: Mo, Clifton C., et al.
Publicado: (2023)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

Assessment of Hypoxia in the Stroma of Patient-Derived Pancreatic Tumor Xenografts
por: Lohse, Ines, et al.
Publicado: (2014)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Selinexor and COVID-19: The Neglected Warden
por: Mostafa-Hedeab, Gomaa, et al.
Publicado: (2022)

SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis
por: Kim, Bo Ram, et al.
Publicado: (2016)

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
por: Garg, Manoj, et al.
Publicado: (2017)

miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer
por: Martini, Silvia, et al.
Publicado: (2021)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis
por: Pham, Nhu-An, et al.
Publicado: (2008)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma
por: Radulovich, Nikolina, et al.
Publicado: (2010)

XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
por: Li, Xuanzong, et al.
Publicado: (2021)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
por: Stiff, Patrick J., et al.
Publicado: (2023)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
por: Lohse, Ines, et al.
Publicado: (2016)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Loss of Canonical Smad4 Signaling Promotes KRAS Driven Malignant Transformation of Human Pancreatic Duct Epithelial Cells and Metastasis
por: Leung, Lisa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_12n9p766pcu350us67obi08kq1